NEW!! SIX buck target. January 10-2023
Joseph Pantginis from H.C. Wainwright & Co. has done a fine job writing an analysis on Sernova. He is both a Ph.D and an M.S in Molecular Genetics and as such his evaluation was made with a very educated mind. His analysis was released the same day that Vertex's trial was put on hold. It makes me think our valuation may have been higher than $6 had Joseph been aware of the FDA decision to put a hold on Vertex's trial. Reports like this one and others are a culmination of many years of efforts and a testament to the future of Sernova. Enjoy the read and try to imagine the fair value of SVA (Patents,ETC) and the CELL pouch. 2023 will be a telling year. Do re-post this link as positive sentiment on all the bullboards will go along ways towards increasing our market cap before potential buyer'S step up.
https://hcwco.com/services/research/meet-our-analysts/#toggle-id-1